US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
イギリス
LSE
Roche Holding Ag (0QQ6)
Roche Holding Ag (0QQ6) ニュース

0QQ6

Roche (0QQ6)

Roche Holding Ag

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QQ6

1

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/10	14 : 05	UK Regulatory	Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization	LSE:0QQ6	Roche Holding Ag
2024/06/10	14 : 00	UK Regulatory	European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer	LSE:0QQ6	Roche Holding Ag
2024/06/07	23 : 40	UK Regulatory	Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk	LSE:0QQ6	Roche Holding Ag
2024/05/29	14 : 00	UK Regulatory	FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
2024/05/27	14 : 00	UK Regulatory	Changes to the Roche Enlarged Corporate Executive Committee	LSE:0QQ6	Roche Holding Ag
2024/05/27	14 : 00	UK Regulatory	Wechsel in der erweiterten Konzernleitung von Roche	LSE:0QQ6	Roche Holding Ag
2024/05/22	14 : 00	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk	LSE:0QQ6	Roche Holding Ag
2024/05/21	14 : 00	UK Regulatory	FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
2024/05/16	14 : 00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity	LSE:0QQ6	Roche Holding Ag
2024/05/15	14 : 00	UK Regulatory	Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer	LSE:0QQ6	Roche Holding Ag
2024/04/24	14 : 00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19	LSE:0QQ6	Roche Holding Ag
2024/04/24	14 : 00	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte	LSE:0QQ6	Roche Holding Ag
2024/04/19	14 : 00	UK Regulatory	FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	LSE:0QQ6	Roche Holding Ag
2024/04/17	15 : 00	UK Regulatory	Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	LSE:0QQ6	Roche Holding Ag
2024/04/15	14 : 00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	LSE:0QQ6	Roche Holding Ag
2024/04/11	14 : 00	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis	LSE:0QQ6	Roche Holding Ag
2024/03/27	01 : 45	UK Regulatory	Roche receives FDA approval for the first molecular test to screen for malaria in blood donors	LSE:0QQ6	Roche Holding Ag
2024/03/12	21 : 30	UK Regulatory	Assemblée générale 2024 de Roche	LSE:0QQ6	Roche Holding Ag
2024/03/12	21 : 30	UK Regulatory	Roche Generalversammlung 2024	LSE:0QQ6	Roche Holding Ag
2024/03/12	21 : 30	UK Regulatory	Roche Annual General Meeting 2024	LSE:0QQ6	Roche Holding Ag
2024/03/05	21 : 30	UK Regulatory	Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	LSE:0QQ6	Roche Holding Ag
2024/02/26	04 : 00	UK Regulatory	New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	LSE:0QQ6	Roche Holding Ag
2024/02/17	01 : 24	UK Regulatory	FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	LSE:0QQ6	Roche Holding Ag
2024/02/01	15 : 03	UK Regulatory	New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	LSE:0QQ6	Roche Holding Ag
2024/02/01	15 : 00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline	LSE:0QQ6	Roche Holding Ag
2024/02/01	15 : 00	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)	LSE:0QQ6	Roche Holding Ag
2024/02/01	15 : 00	UK Regulatory	[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19	LSE:0QQ6	Roche Holding Ag
2023/10/23	20 : 18	IH Market News	Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more	LSE:0QQ6	Roche Holding Ag

Showing the most relevant articles for your search:LSE:0QQ6

1

Financial Select Sector

Invesco QQQ Trust Series 1

US Dollar vs Sterling

Gold vs US Dollar

BNP Paribas (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約